NCT04319601

Rituximab Combined With Chidamide and Lenalidomide for r/r AITL

A Single-arm, Multiple Centers, Phase II Study Evaluating Rituximab in Combination With Chidamide and Lenalidomide for Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma (AITL)

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 26 (estimated)
• Sponsor: Zhejiang Cancer Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to explore the effeicency and toxicities of rituximab combined with chidamide and lenalidomide in patients with relapsed or refractory AITL.

Detailed description

This study is designed to explore the effeicency and toxicities of rituximab combined with chidamide and lenalidomide in patients with relapsed or refractory AITL. The primary end point is PFS, and second end point is OS, ORR and toxicities according to CTCAE 5.0.

Conditions

• Angioimmunoblastic T-cell Lymphoma
• Chemotherapy Effect
• Chemotherapeutic Toxicity

Interventions

Type	Name	Description
DRUG	Rituximab	a new chemotherapy regimen

Timeline

• Start date: 2020-03-13
• Primary completion: 2022-03-31
• Completion: 2022-12-31
• First posted: 2020-03-24
• Last updated: 2021-03-24

Locations

1 site across 1 country: China